Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 31 AL 45

Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease

Baptista FI, Henriques AG, Silva AM, Wiltfang J, da Cruz e Silva OA.

ACS Chem Neurosci. 2014 Feb 19;5(2):83-92. doi: 10.1021/cn400213r. Epub 2014 Jan 3.

Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis

Wood WG, Li L, Müller WE, Eckert GP.

J Neurochem. 2014 May;129(4):559-72. doi: 10.1111/jnc.12637. Epub 2014 Jan 2.

A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease

Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls AP, Boardley RL, Berges AC, Nathan PJ, Horrigan JP.

Curr Alzheimer Res. 2014 Jan;11(1):47-58. doi: 10.2174/1567205010666131212110148.

Wnt/β-catenin signaling in Alzheimer's disease

De Ferrari GV, Avila ME, Medina MA, Perez-Palma E, Bustos BI, Alarcon MA.

CNS Neurol Disord Drug Targets. 2014;13(5):745-54. doi: 10.2174/1871527312666131223113900.

Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease

Aliev G, Priyadarshini M, Reddy VP, Grieg NH, Kaminsky Y, Cacabelos R, Ashraf GM, Jabir NR, Kamal MA, Nikolenko VN, Zamyatnin AA Jr, Benberin VV, Bachurin SO.

Curr Med Chem. 2014;21(19):2208-17. doi: 10.2174/0929867321666131227161303.

Vitamin E, memantine, and Alzheimer disease

Evans DA, Morris MC, Rajan KB.

JAMA. 2014 Jan 1;311(1):29-30. doi: 10.1001/jama.2013.282835.

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial

Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD.

JAMA. 2014 Jan 1;311(1):33-44. doi: 10.1001/jama.2013.282834.

Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease

Iqbal K, Gong CX, Liu F.

Expert Opin Ther Targets. 2014 Mar;18(3):307-18. doi: 10.1517/14728222.2014.870156. Epub 2014 Jan 3.

Emerging therapeutics for Alzheimer's disease

Chiang K, Koo EH.

Annu Rev Pharmacol Toxicol. 2014;54:381-405. doi: 10.1146/annurev-pharmtox-011613-135932.

Omega-3 fatty acids: a growing ocean of choices

Fares H, Lavie CJ, DiNicolantonio JJ, O'Keefe JH, Milani RV.

Curr Atheroscler Rep. 2014 Feb;16(2):389. doi: 10.1007/s11883-013-0389-6.

Intranasal therapeutic strategies for management of Alzheimer's disease

Sood S, Jain K, Gowthamarajan K.

J Drug Target. 2014 May;22(4):279-94. doi: 10.3109/1061186X.2013.876644. Epub 2014 Jan 9.

The treatment of Alzheimer's disease using Chinese medicinal plants: from disease models to potential clinical applications

Su Y, Wang Q, Wang C, Chan K, Sun Y, Kuang H.

J Ethnopharmacol. 2014 Mar 28;152(3):403-23. doi: 10.1016/j.jep.2013.12.053. Epub 2014 Jan 9.

Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer's Disease

Sharma A, Bemis M, Desilets AR.

Am J Alzheimers Dis Other Demen. 2014 Aug;29(5):409-14. doi: 10.1177/1533317513518650. Epub 2014 Jan 9.

Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease

Marek GJ, Katz DA, Meier A, Greco N 4th, Zhang W, Liu W, Lenz RA.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S364-73. doi: 10.1016/j.jalz.2013.09.010. Epub 2014 Jan 10.

γ-Secretase modulators: current status and future directions

Hall A, Patel TR.

Prog Med Chem. 2014;53:101-45. doi: 10.1016/B978-0-444-63380-4.00003-2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias